Butterfly Network Partners With Merge Labs on Ultrasound BCI
BURLINGTON, Mass. & NEW YORK, September 1, 2026 Butterfly Network, Inc. and Merge Labs have entered a multi-year licensing...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BURLINGTON, Mass. & NEW YORK, September 1, 2026 Butterfly Network, Inc. and Merge Labs have entered a multi-year licensing...
Fort Mill, S.C. – August 27, 2026 Catheter Precision, Inc. announced several commercial milestones for its LockeT® and VIVO™...
Redwood City, California, August 20, 2026 Galvanize Therapeutics, Inc. has announced new peer-reviewed evidence suggesting that its Aliya® pulsed...
Menlo Park, California, August 20, 2026 Subtle Medical, a provider of AI-powered medical imaging solutions, has appointed Lawrence N....
Tel Aviv, Israel, August 19, 2026 Galmed Pharmaceuticals announced successful first-in-human proof-of-concept results for a novel intraoperative tissue assessment...
Santa Clara, California, August 17, 2026 Johnson & Johnson announced U.S. 510(k) regulatory clearance for MONARCHâ„¢ QUEST 3, the...
Tinley Park, Illinois, August 19, 2026 Hematogenix has announced that its proprietary Multiple Myeloma Minimal Residual Disease (MM MRD)...
Newport Beach, California, August 19, 2026 Renata Medical, a medical technology company focused on pediatric congenital heart disease (CHD),...
VALENCIA, Calif., August 18, 2026 AVITA Medical, Inc. announced positive results from the multicenter, randomized controlled PermeaDerm-I clinical study,...
DURHAM, N.C., August 18, 2026 Humacyte, Inc. announced that its FDA-approved bioengineered blood vessel Symvess® has entered commercial use...
